Jason B. Shandell Sells 700 Shares of Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) Stock

Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) insider Jason B. Shandell sold 700 shares of the company’s stock in a transaction that occurred on Wednesday, March 14th. The stock was sold at an average price of $20.45, for a total value of $14,315.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Jason B. Shandell also recently made the following trade(s):

How to Become a New Pot Stock Millionaire
  • On Thursday, January 25th, Jason B. Shandell sold 8,661 shares of Amphastar Pharmaceuticals stock. The stock was sold at an average price of $19.26, for a total value of $166,810.86.
  • On Friday, January 26th, Jason B. Shandell sold 18,627 shares of Amphastar Pharmaceuticals stock. The stock was sold at an average price of $19.42, for a total value of $361,736.34.

AMPH opened at $19.01 on Friday. Amphastar Pharmaceuticals Inc has a 1-year low of $13.15 and a 1-year high of $20.45. The company has a current ratio of 2.79, a quick ratio of 1.85 and a debt-to-equity ratio of 0.12. The firm has a market capitalization of $881.13, a P/E ratio of 50.03, a price-to-earnings-growth ratio of 1.35 and a beta of 1.42.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last posted its quarterly earnings results on Monday, March 12th. The company reported $0.10 earnings per share for the quarter, beating analysts’ consensus estimates of $0.07 by $0.03. Amphastar Pharmaceuticals had a return on equity of 4.56% and a net margin of 1.88%. The business had revenue of $60.40 million for the quarter, compared to analysts’ expectations of $60.62 million. During the same quarter in the prior year, the business earned $0.01 EPS. The firm’s revenue for the quarter was down 4.9% on a year-over-year basis. equities analysts expect that Amphastar Pharmaceuticals Inc will post 0.63 earnings per share for the current year.

A number of brokerages have recently issued reports on AMPH. Wells Fargo reiterated a “buy” rating on shares of Amphastar Pharmaceuticals in a research note on Wednesday, March 21st. Zacks Investment Research cut Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, March 13th. BMO Capital Markets reiterated a “market perform” rating and set a $19.00 price objective (up previously from $17.00) on shares of Amphastar Pharmaceuticals in a research note on Tuesday, March 13th. Needham & Company LLC reiterated a “buy” rating and set a $24.00 price objective (up previously from $23.00) on shares of Amphastar Pharmaceuticals in a research note on Tuesday, March 13th. Finally, BidaskClub upgraded Amphastar Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, March 13th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and four have given a buy rating to the stock. Amphastar Pharmaceuticals presently has an average rating of “Hold” and an average target price of $21.33.

Hedge funds have recently bought and sold shares of the business. Paloma Partners Management Co bought a new position in Amphastar Pharmaceuticals during the 4th quarter worth $197,000. Stone Ridge Asset Management LLC bought a new position in Amphastar Pharmaceuticals during the 4th quarter worth $214,000. Renaissance Technologies LLC bought a new position in Amphastar Pharmaceuticals during the 4th quarter worth $227,000. Driehaus Capital Management LLC bought a new position in Amphastar Pharmaceuticals during the 4th quarter worth $229,000. Finally, Municipal Employees Retirement System of Michigan increased its position in Amphastar Pharmaceuticals by 58.8% during the 3rd quarter. Municipal Employees Retirement System of Michigan now owns 13,390 shares of the company’s stock worth $239,000 after buying an additional 4,960 shares during the period. Hedge funds and other institutional investors own 44.46% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This story was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this story on another website, it was illegally copied and republished in violation of US and international copyright and trademark laws. The original version of this story can be accessed at https://www.dispatchtribunal.com/2018/04/08/amphastar-pharmaceuticals-inc-amph-insider-jason-b-shandell-sells-700-shares-of-stock.html.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.

Insider Buying and Selling by Quarter for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply